Kisqali was approved for the new indication on the back of the NATALEE trial, in which adding Kisqali to standard treatment ...

EVERSANA has launched a new pharmacovigilance (PV) platform that answers the need to apply advanced data analytics and artificial intelligence to drug safety monitoring and risk management.